

University of Massachusetts Medical School

eScholarship@UMMS

---

UMass Center for Clinical and Translational  
Science Research Retreat

2014 UMass Center for Clinical and  
Translational Science Research Retreat

---

May 20th, 12:30 PM

## Targeted Mutagenesis of a Therapeutic Human Monoclonal IgG1 Antibody Prevents Gelation at High Concentrations

Paul Casaz

*University of Massachusetts Medical School*

*Et al.*

Let us know how access to this document benefits you.

Follow this and additional works at: [https://escholarship.umassmed.edu/cts\\_retreat](https://escholarship.umassmed.edu/cts_retreat)



Part of the Amino Acids, Peptides, and Proteins Commons, Biotechnology Commons, Immunoprophylaxis and Therapy Commons, Molecular Biology Commons, Therapeutics Commons, Translational Medical Research Commons, and the Virology Commons

---

Casaz P, Boucher EN, Wollacott R, Ozturk SS, Thomas WD, Wang Y. (2014). Targeted Mutagenesis of a Therapeutic Human Monoclonal IgG1 Antibody Prevents Gelation at High Concentrations. UMass Center for Clinical and Translational Science Research Retreat. Retrieved from [https://escholarship.umassmed.edu/cts\\_retreat/2014/posters/28](https://escholarship.umassmed.edu/cts_retreat/2014/posters/28)

Creative Commons License



This work is licensed under a [Creative Commons Attribution-Noncommercial-Share Alike 3.0 License](https://creativecommons.org/licenses/by-nc-sa/3.0/).

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For more information, please contact [Lisa.Palmer@umassmed.edu](mailto:Lisa.Palmer@umassmed.edu).

## **Targeted mutagenesis of a therapeutic human monoclonal IgG1 antibody prevents gelation at high concentrations.**

Paul Casaz, Elisabeth Boucher, Rachel Wollacott, Sadettin Ozturk, William Thomas, Jr and Yang Wang

MassBiologics of the University of Massachusetts Medical School  
460 Walk Hill Street, Boston, MA 02126

Corresponding Author: Yang.Wang@umassmed.edu, 617-474-4091

A common challenge encountered during development of high concentration monoclonal antibody formulations is preventing self-association. Depending on the antibody and its formulation, self-association can be seen as aggregation, precipitation, opalescence or phase separation. Here we report on an unusual manifestation of self-association, formation of a semi-solid gel or “gelation”. Therapeutic monoclonal antibody C4 was isolated from human B cells based on its strong potency in neutralizing bacterial toxin in animal models. The purified antibody possessed the unusual property of forming a firm, opaque white gel when it was formulated at concentrations >40 mg/mL and the temperature was <6°C. Gel formation was reversible and was affected by salt concentration or pH, suggesting a charge interaction between IgG monomers. However, formulation optimization could not completely prevent gelation at high concentrations so a protein engineering approach was sought to resolve the problem.

A comparison of the heavy and light chain amino acid sequences to consensus germline sequences revealed 16 amino acid sequence differences in the framework regions that could be involved with gelation. Restoring the C4 framework sequence to consensus germline residues by targeted mutagenesis resulted in no gel formation at 50 mg/ml at temperatures as low as 0°C. Additional genetic analysis was used to identify the key residue(s) involved in the gelation. A single substitution in the native antibody, replacing heavy chain glutamate 23 with lysine, was found sufficient to prevent gelation, while a double mutation, replacing heavy chain serine 85 and threonine 87 with arginine, increased the temperature at which gel formation initiated. These results indicate that the temperature dependence of gelation may be related to conformational changes near the charged residues or the regions interact with. Our work provided a molecular strategy that can be applied to improve the solubility of other therapeutic antibodies.